UPDATED Apr 16, 2024
Popular and high growth companies which might be overvalued.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
NCH2 | €12.30 | -9.7% | n/a | €1.6b | €21.80 | PE92.5x | E39.1% | n/a | Capital Goods | ||
FYB | €45.20 | -2.3% | -31.4% | €798.2m | €96.25 | PS11.6x | E83.5% | n/a | Pharmaceuticals & Biotech | ||
INS | €8.96 | 3.0% | 13.0% | €388.2m | €10.13 | PE19.3x | E23.4% | 3.7% | Real Estate Management and Development | ||
NF4 | €44.40 | -0.9% | 16.8% | €103.3m | €67.00 | PE121.3x | E60.2% | 0.6% | Diversified Financials |